Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482011 | 0.74 | CYP11B2 (0.41) | — | |
| SCHEMBL13452595 | 0.72 | HRH3 (0.49) | ADRA2ACHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13452622 | 0.71 | ADRA2A (0.43) | ADRA2ACHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2210053 | 0.70 | KAT2B (0.43) | ADRA2ACHRNB2CHRNA4 | |
| SCHEMBL29519954 | 0.70 | HRH3 (0.46) | CYP1A2 | |
| SCHEMBL13452389 | 0.70 | NOS1 (0.41) | ADRA2ACYP1A2CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL481835 | 0.69 | CYP1A2 (0.48) | CYP1A2 | |
| SCHEMBL11473707 | 0.68 | ALDH1A1 (0.49) | ADRA2ACYP1A2 | |
| SCHEMBL12090382 | 0.67 | HRH3 (0.54) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22230354 | 0.66 | LMNA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | ADRA2A 1808/4885CYP1A2 997/4885CHRNB1 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.